Method for peritoneal removal of electrolytes and inflammatory mediators

ABSTRACT

A method of peritoneal removal of electrolytes and inflammatory mediators. The method begins with infusing a treatment solution into the peritoneal cavity of a patient by way of a catheter. The treatment solution is drained from the peritoneal cavity by way of the catheter. During the draining, the treatment solution is filtered for removing electrolytes and inflammatory mediators.

Pursuant to 37 C.F.R. § 1.78(a)(4), this application claims the benefitof and priority to prior filed co-pending Provisional Application Ser.No. 62/410,135, filed Oct. 19, 2016, which is expressly incorporatedherein by reference.

RIGHTS OF THE GOVERNMENT

The invention described herein may be manufactured and used by or forthe Government of the United States for all governmental purposeswithout the payment of any royalty.

FIELD OF THE INVENTION

The present invention relates generally to peritoneal dialysis and, moreparticularly, to methods of binding electrolytes or inflammatorymediators.

BACKGROUND OF THE INVENTION

While severe illness or injury is, in itself, difficult for the patientand physician treatment, these conditions are often further complicatedby increased levels of electrolytes and inflammatory mediators.Conventionally, electrolyte removal involves renal replacement therapy,which requires significant supplies and personnel. Such demands onresources makes in-field treatment at least difficult if not impossible.Likewise, inflammatory mediators are conventionally removed viacontinuous venovenous hemodialysis, plasma exchange, or hemoperfusion.Again, there is a significant requirement of resources, thus limiting ituse during deployment.

In either instance, treatment requires large bore catheterization to amajor vein. For example, FIG. 1 illustrates one conventional renalreplacement therapy treatment system 20 in which a venous access is madeby way of a jugular vein 22 of a patient 24. A large bore catheter 26extends from the jugular 22 and is fluidically coupled to an externallypositioned blood filter 28. Oftentimes, a replacement fluid 30 may beintroduced to the line 32 before the filter 28 (as illustrated), afterthe filter (not shown), or both. The replacement fluid 30 may compriseelectrolytes and other chemical agents prone to removal during dialysis.A dialysate 34 is supplied to the filter 28, but such that the dialysate34 is fluidically separated from the blood (such as by a semipermeablemembrane 36 (FIG. 1A)) and in a direction of flow (arrow 38, FIG. 1A)that counters a direction of the blood flow (arrow 40, FIG. 1A). Thus,waste dialysate with other filtered waste products may be removed aspart of an effluent 42. In any event, the dialysate 34 is configured tocreate a concentration gradient that draws small molecule wastes andelectrolytes out of the blood flow (arrow 40), across the semipermeablemembrane 36, and into the dialysate flow (arrow 38) at the effluent 42.Cleaned blood may then flow via another blood line 44 to the jugular 22.

While the exemplary system of FIG. 1 provides a significant benefit topatients, there remains need for improvements, particularly for use inthe deployment field or for in-the-field use. For example, theillustrated treatment often creates complications in possiblehemodynamic instability and typically requiring anticoagulation.

Given such difficulties in treating complications associated illness andinjury, there remains a need for methods of peritoneal removing ofelectrolytes and inflammatory mediators that minimizes the need ofresources and thus accessible for deployment and in-the-filed use.

SUMMARY OF THE INVENTION

The present invention overcomes the foregoing problems and othershortcomings, drawbacks, and challenges of conventional methods ofremoving peritoneal electrolytes and inflammatory mediators. While theinvention will be described in connection with certain embodiments, itwill be understood that the invention is not limited to theseembodiments. To the contrary, this invention includes all alternatives,modifications, and equivalents as may be included within the spirit andscope of the present invention.

According to an embodiment of the present invention, a method ofperitoneal removal of electrolytes and inflammatory mediators beginswith infusing a treatment solution into the peritoneal cavity of apatient by way of a catheter. The treatment solution is drained from theperitoneal cavity by way of the catheter. During the draining, thetreatment solution is filtered for removing electrolytes andinflammatory mediators.

In accordance with other embodiments of the present invention, themethod includes elevating a treatment solution container above aninfusion site of a patient such that the treatment solution infuses intothe peritoneal cavity of the patient by way of a catheter. The treatmentsolution container may be lowered to below the infusion site so as todrain the treatment solution from the peritoneal cavity. Electrolytesand inflammatory mediators may be filtered from the treatment solutionduring infusion, during draining, or both.

Yet other embodiments of the present invention are directed to a methodof peritoneal removal of electrolytes and inflammatory mediators andincludes implanting a filter cartridge into the peritoneal cavity of apatient. The filter cartridge includes a binding agent enclosed within aporous surgical packing material. A treatment solution is infused intothe peritoneal cavity of the patient and drawn from the peritonealcavity by way of the filter cartridge.

Additional objects, advantages, and novel features of the invention willbe set forth in part in the description which follows, and in part willbecome apparent to those skilled in the art upon examination of thefollowing or may be learned by practice of the invention. The objectsand advantages of the invention may be realized and attained by means ofthe instrumentalities and combinations particularly pointed out in theappended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute apart of this specification, illustrate embodiments of the presentinvention and, together with a general description of the inventiongiven above, and the detailed description of the embodiments givenbelow, serve to explain the principles of the present invention.

FIG. 1 is a schematic illustration of a renal replacement therapytreatment system according to the prior art.

FIG. 1A is an enlarged portion of FIG. 1.

FIG. 2 is a flow chart illustrating a method of using a peritonealdialysis system according to an embodiment of the present invention.

FIG. 3 is a schematic illustration of a peritoneal dialysis systemaccording to an exemplary embodiment of the present invention.

FIG. 3A is an enlargement of the portion identified in FIG. 3.

FIGS. 4A-4G are diagrammatic views illustrating successive steps of oneexemplary procedure for implementing a peritoneal dialysis system.

FIG. 5 is a diagrammatic illustration of a method of using a peritonealdialysis system according to an embodiment of the present invention.

FIG. 6 is a flow chart illustrating a method of using a peritonealdialysis system according to another embodiment of the presentinvention.

FIG. 7A-7D are diagrammatic views illustrating successive steps of oneexemplary procedure for implanting the peritoneal dialysis system ofFIG. 8.

FIG. 8 is a schematic illustration of a peritoneal dialysis systemaccording to another exemplary embodiment of the present invention.

It should be understood that the appended drawings are not necessarilyto scale, presenting a somewhat simplified representation of variousfeatures illustrative of the basic principles of the invention. Thespecific design features of the sequence of operations as disclosedherein, including, for example, specific dimensions, orientations,locations, and shapes of various illustrated components, will bedetermined in part by the particular intended application and useenvironment. Certain features of the illustrated embodiments have beenenlarged or distorted relative to others to facilitate visualization andclear understanding. In particular, thin features may be thickened, forexample, for clarity or illustration.

DETAILED DESCRIPTION OF THE INVENTION

Referring now to the figures, and in particular to FIGS. 2 and 3 (andreference to FIGS. 3A-6), a flowchart 50 illustrating a method ofperitoneal dialysis configured to remove electrolytes and inflammatoryagents according to a first embodiment of the present invention isdescribed. At start, a peritoneal catheter 52 is surgically placedwithin the peritoneal cavity 54 of a patient 56 (Block 58). Insertion ofthe peritoneal catheter 52 may be accomplished via orthoscopicprocedures, percutaneous procedures, or open surgical procedures. Forpurposes of illustration of a first embodiment of the present invention,a percutaneous procedure is illustrated. Additionally, to facilitateillustration, certain anatomical landmarks are also illustrated in FIG.3, including the liver 60, stomach 62, vertebra bodies 64, spinousprocesses 66, and intervertebral discs 68.

Referring now to FIG. 4A, a small incision 70 is made using a bluntdissection tool, such as a scalpel 72. As is shown, the incision 70 maybe along the midline, but the position of the incision 70 is notlimiting and may be otherwise positioned if needed or desired by thesurgeon. Further, it will be understood by those of ordinary skill inthe art of percutaneous surgical procedures that the referencedillustrations are not necessarily to scale.

As illustrated in FIG. 4B, after the incision 70 is made, a needle 74(illustrated in partial cross section) is inserted through the incision70 and into the peritoneal cavity 54 (FIG. 3). While the specifics ofthe needle 74 are not necessary, for purposes of explanation, a suitableneedle 74 may include an 18 gauge needle. To ensure appropriatepositioning of the needle 74 and to increase maneuverability within theperitoneal cavity 54 (FIG. 3). Although not specifically illustratedhere, air or saline may be injected into the peritoneal cavity 54 (FIG.3) by way of the needle 74. While the volume of air or saline may varyand depends on a particular size of the patient's anatomy, 500 mL may beappropriate.

FIG. 4B further illustrates insertion of a guidewire 76 through a lumen(defined by an inner wall 78) of the needle 74 and into the inflatedperitoneal cavity 54 (FIG. 3). With a distal end 80 of the guidewire 76extending through the incision 70 and into the peritoneal cavity 54(FIG. 3), the needle 74 may be retracted, over the length of theguidewire 76, and removed from a proximal end (not shown) of theguidewire 76. As such, the guidewire 46 remains positioned for receivingand guiding appropriate devices into the peritoneal cavity 54 (FIG. 3).

FIGS. 4C-4E illustrate insertion of a delivery sheath 82, optionallywith a dilator 84, into the peritoneal cavity 54 (FIG. 3) by way of theguidewire 76. Specifically, in FIG. 4C, the optionally dilator 84 ispositioned within a lumen (not shown) of the delivery sheath 82 suchthat a tapered distal end 86 of the dilator 84 extends distally awayfrom a distal end 88 of the delivery sheath 82. Relative positioning ofthe dilator 84 and delivery sheath 82 may be secured in a manner that isknown to the skilled surgeon. Suitable dilators 84 may include, but arenot limited to, a rigid obturator, an inflatable dilating balloon, orother suitable dilator instrument.

The combination dilator 84 and delivery sheath 82 are directed, inunison, over the guidewire 76 toward the incision 70. As the dilator 84and delivery sheath 82 move across the incision 70 and into theperitoneal cavity 54 (FIG. 3), the tapered end 86 of the dilator 84dilates and expands the incision 70 such that the delivery sheath 82 maybe received into the peritoneal cavity 54 (FIG. 3), which is shown inFIG. 4D.

As shown in FIG. 4E, once the delivery sheath 82 is in place, thedilator 86 may be retracted and removed while the distal end 88 of thedelivery sheath 82 remains positioned within the peritoneal cavity 54(FIG. 3).

Looking now to FIG. 4F, the peritoneal catheter 52 may be advanced intothe peritoneal cavity 54 (FIG. 3) by passing the catheter 52 through alumen (not shown) of the delivery catheter 82. The particular peritonealcatheter 52 used may vary, but is generally selected from straight, swanneck, and coiled. If a coiled catheter is used, then, optionally, aremovable stylet (not shown) may be positioned within a lumen of thecoiled peritoneal catheter so as to resist coiling of the distal end ofthe catheter as the catheter emerges from the distal end 88 of thedelivery sheath 82. Otherwise, the lumen (not shown) of the deliverysheath 82 may be sufficient to maintain the peritoneal catheter 52 in arelatively straight configuration until positioning within theperitoneal cavity 54 (FIG. 3) is complete. Thus, while FIGS. 4F and 4Gillustrate use of a coiled peritoneal catheter 54, specific use of astylet is not illustrated. Instead, as a distal end 90 of the peritonealcatheter 54 extends distally away from the distal end 88 of the deliverysheath 82, the distal end 90 of the catheter 52 may begin to coil.Further distally directed advancement of the catheter 52 through thedelivery sheath 82 and into the peritoneal cavity 54 (FIG. 3) may permitfurther coiling of the distal end 90 of the peritoneal catheter 52, asshown in FIG. 3.

Referring again to FIG. 3, proper positioning of the peritoneal catheter52 may be facilitated by way of one or more cuffs, which is more clearlyshown in enlarged FIG. 3A. Specifically as illustrated, the peritonealcatheter 52 includes a first cuff 92 and a second cuff 94 positionedproximally to the first cuff 92. The first and second cuffs 92, 94 maybe spaced along the peritoneal catheter 52 by a distance that isapproximately equal to a thickness of the abdominal wall of the patient56. In use, the surgeon may advance the peritoneal catheter 52 until thefirst cuff 92 is located within the peritoneal cavity 54. It would beunderstood that other catheters having only one cuff or no cuffs mayalso be used.

Turning now to FIG. 4G, and with the peritoneal catheter 52 suitablypositioned within the peritoneal cavity 54 (FIG. 3), the delivery sheath82 (FIG. 4F) may be removed. Removal may include retraction andwithdrawal of the delivery sheath 82 (FIG. 4F) from the peritonealcavity 54 (FIG. 3), the incision 70, and the catheter 52. Alternatively,the delivery sheath 82 (FIG. 4F) may comprise a peel-a-way materialknown by those of ordinary skill in the art. In that way, the deliverysheath 82 (FIG. 4F) may be split and peeled away from the catheter 52and disposed.

Optionally, if necessary, the incision 70 may be closed to furthersecure placement of the catheter 52 within the peritoneal cavity 54(FIG. 3).

Referring again to FIGS. 2 and 3, with the peritoneal catheter 52positioned and secured, a proximal end 96 of the catheter 52 may becoupled a treatment solution source 98. Specifically as shown, theproximal end 96 of the catheter 52 is coupled to a first port 100 of athree-way valve 102. Two additional ports 104, 106 of the three-wayvalve 102 (second and third respectively) are further coupled toadditional catheters 108, 110 of which one is operably coupled to thetreatment solution source 98 and the other is operably coupled to aliquid storage tank 112.

Fluid flow through the three-way valve 102 may be configured such thattreatment solution flows into and through the peritoneal catheter 52 andinto the peritoneal cavity 54, permitting the treatment solution to beinstilled into the cavity 54 (Block 114). The treatment solutioncomprises saline with optional binding agents. According to someembodiments of the present invention, the binding agents may bechelators configured to absorb inflammatory mediators, metals, or othersolutes from the peritoneal cavity 54.

After a period of time, sufficient for achieving equilibration, thetreatment solution may be drained from the peritoneal cavity 52, via theperitoneal catheter 52 and three-way valve 106 to the fluid storage tank112 (Block 116). The treatment solution is filtered (Block 118), whichmay accomplished after being drained into the fluid storage tank 112 or,as specifically illustrated, as the treatment solution flows through thecatheter 110 extending between the three-way valve 106 and the fluidstorage tank 112. As such, the fluid path along the catheter 110includes a filter 120 configured to remove inflammatory mediators.

According to some embodiments of the present invention, the filter 120may incorporate a polymer, such as those described in U.S. ApplicationPublication No. 2013/0195792, entitled METHOD OF TREATING INFLAMMATION,and filed on Apr. 1, 2011; U.S. Application Publication No.2014/0294751, entitled HEMOCOMPATIBILITY MODIFIERS FOR CROSS-LINKEDPOLYMERIC MATERIAL, and filed Mar. 31, 2014; or U.S. ApplicationPublication no. 2015/0118673, entitled POLYMERIC SORBENT FOR REMOVAL OFIMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS, and filed Aug. 10, 2012.Such polymer is configured to remove inflammatory mediators via theprinciple of size exclusion (molecules of the intended size are trappedwithin the polymer structure). According to other embodiments of thepresent invention, binding agents may comprise resins, diffusion tubes,or other novel binding agents, including, for example, those that aredescribed in U.S. Pat. No. 8,216,560, issued on Jul. 10, 2012, andentitled ION BINDING POLYMERS AND USES THEREOF.

Once the treatment solution has drained into the fluid storage tank 112,and filtered, a determination as to whether further dialysis is made(Decision Block 122). Such determination may include, for example,laboratory analysis of the blood, analysis of electrocardiogram, orclinical evaluation by a physician. If further dialysis is required(“YES” branch of decision block 122), then a further determination as towhether the treatment solution is spent is made (Decision Block 124).Said another way, if the drained and filtered treatment solution withinthe fluid storage tank 112 has inflammatory mediators above a thresholdconcentration (“YES” branch of decision block 124), then the process mayreturn to instilling clean treatment solution into the peritoneal cavity(Block 114). However, if the concentration of inflammatory mediatorswithin the drained and filtered treatment solution in the fluid storagetank 112 is below such threshold concentration (“NO” branch of decisionblock 124), then treatment solution within the fluid storage tank 112may be instilled into the peritoneal cavity 52 (Block 126) and theprocess continues.

If further dialysis is neither required nor desired (“NO” branch ofdecision block 122), then the process ends.

An alternative embodiment of the present invention is illustrated inFIG. 5. More particularly the peritoneal cavity 54 may be fluidicallycoupled to a treatment solution container 130 via a catheter 132 havinga filter 134 along the fluid path. At start, the treatment solutioncontainer 130 may be elevated to above a level (illustrated by a dashedline 136) of the peritoneal cavity 54. The treatment solution thus flowsdown, by gravity, from the treatment solution container 130, through thefilter 134, to the peritoneal cavity 54. After a time suitable forreaching equilibration, the treatment solution container 130 may belowered to below the level (line 136) such that the treatment solutiondrains, by gravity, from the peritoneal cavity 54, through the filter134 and to the treatment solution container 130. While the treatmentsolution drains and flows through the filter, electrolytes andinflammatory mediators, or both, are removed from solution, as describedpreviously. Once these substances are filtered and bound, the treatmentsolution container 130 may then, again, be raised such that thetreatment solution is re-instilled into the peritoneal cavity 54. Theprocess may be repeated until the therapeutic effect has been achieved(e.g., resolution of hyperkalemia).

While not specifically illustrated, yet another embodiment is envisionedin which the filter may be incorporated into the treatment solutioncontainer 130 as opposed to being an inline filter.

With reference now to FIGS. 6-8, a method 140 of peritoneal dialysisaccording to other embodiments of the present invention is shown. Whilethis particular illustrated embodiment incorporates an open surgicalprocedure, it would be understood that the method could be performed inother ways, such a laparoscopically. While not necessary, thisparticular embodiment of the present invention is likely to be used whenthe abdomen 142 of the patient 144 is opened during a planned traumasurgery. Nonetheless, as shown in FIG. 7A, an incision 146 may becreated with a scalpel 147 in the subcutaneous layer dissected to andthrough the sheath of the rectus abdominal muscle. Thereafter, theperitoneum is dissected, the peritoneal cavity 148 opened and inspectedfor adhesions (FIG. 7B). FIG. 7B specifically illustrates the peritonealcavity 148 with the liver 150, stomach 152, and intestines 154 exposed(Block 156).

In FIG. 7C, an implantable cartridge 158, according to an embodiment ofthe present invention, may be placed within the peritoneal cavity 148(Block 160). The implantable cartridge 158, which is illustrated withgreater detail in FIG. 8, comprises binding agents 162, describedpreviously, enclosed or others sandwiched between porous surgicalpacking materials 164, which may include gauze, laparotomy pads, orsponges.

While the implantable cartridge 158 is within the peritoneal cavity 148,electrolytes and inflammatory mediators, for example, potassium, mayflow down a concentration gradient into that fluid. In the setting ofhyperkalemia, the concentration of potassium can be 6 meq/L. Withstandard peritoneal dialysis, if 2 L of fluid (with a concentration of 0meq/L of potassium) are infused into the peritoneum, potassium will flowdown a concentration gradient until the concentrations equalize and atotal of 12 meq (6 meq/L×2 L) will be removed. However once theconcentrations equilibrate, no further substances transmit from theblood. The same process occurs for other electrolytes and inflammatorymediators. However, with the implantable cartridge 158 in the peritonealcavity 148, the potassium would be bound, keeping the potassiumconcentration in the fluid at close to 0 meq/L, which would enablecontinued removal without exchange of fluid.

The position of the cartridge 158 may be largely dependent on surgeonpreference, but should generally be in a location have sufficientsurface area. To increase surface area available for binding, fluid maybe instilled into the peritoneal cavity 148.

Turning now to FIG. 7D, with continued reference to FIGS. 6 and 8, awound drain 166 and pump 168 may optionally applied to the surgical sitein close proximity to the cartridge 158 (FIG. 7C) (Block 170). Furtheroptionally, as illustrated, a fluid port of the pump 168 may befluidically coupled to another catheter 172 that may lead to theperitoneal cavity 148. A filter 174, in accordance with those describedin greater detail above, may be in fluid communication with and alongthe fluid path of the catheter 172.

If desired, the surgical opening may then be closed (Block 176). Withthe pump activated, a wound vacuum is applied (Block 178). In sucharrangement, fluid extracted from the peritoneal cavity 148 by way ofthe wound drain 166 and pump 158 may be filtered and re-instilled tointo the peritoneal cavity 158.

The patient 144 may be monitored (Block 180) until such a time that thecartridge 158, drain 166, pump 168, and filter 174 are no longerrequired and, thus, removed (Block 182).

While the present invention has been illustrated by a description of oneor more embodiments thereof and while these embodiments have beendescribed in considerable detail, they are not intended to restrict orin any way limit the scope of the appended claims to such detail.Additional advantages and modifications will readily appear to thoseskilled in the art. The invention in its broader aspects is thereforenot limited to the specific details, representative apparatus andmethod, and illustrative examples shown and described. Accordingly,departures may be made from such details without departing from thescope of the general inventive concept.

What is claimed is:
 1. A method of peritoneal removal of electrolytesand inflammatory mediators, the method comprising: infusing a treatmentsolution into the peritoneal cavity of a patient by way of a catheter;draining, by way of the catheter, the treatment solution from theperitoneal cavity; and filtering electrolytes and inflammatory mediatorsfrom the treatment solution while the treatment solution is draining. 2.The method of claim 1, wherein filtering electrolytes and inflammatorymediators further comprises: positioning a filter in fluid communicationwith the catheter, the filter comprising: a proximal end; a distal end;a lumen extending between the proximal and distal ends; and a fillerwithin the lumen of the filter, the filler configured to removeelectrolytes, inflammatory mediators, or both by size exclusion.
 3. Themethod of claim 2, wherein the filler is selected from the groupconsisting of: a polymer, a resin, or diffusion tubes configured toremove inflammatory mediators.
 4. The method of claim 2, the fillercomprising a binding agent configured to selectively bind electrolytes,inflammatory mediators, or both.
 5. The method of claim 4, wherein thebinding agent is selected from the group consisting of: a polymer, aresin, or diffusion tubes configured to remove inflammatory mediators.6. The method of claim 1, wherein infusing the treatment solutionfurther comprises: a treatment solution container fluidically coupled toa distal end of the catheter, the treatment solution containerconfigured to support the treatment solution.
 7. The method of claim 6,wherein infusing the treatment solution further comprises: elevating thetreatment solution container above an infusion site of the patient. 8.The method of claim 6, wherein draining the treatment solution furthercomprises: lowering the treatment solution container below an infusionsite of the patient.
 9. The method of claim 6, further comprising:elevating the treatment solution container above an infusion site of thepatient for infusing the treatment solution; and lowering the treatmentsolution container below the infusion site for draining the treatmentsolution.
 10. The method of claim 1, wherein the treatment solutioncomprises: saline; and a binding agent configured to selectively bindelectrolytes, inflammatory mediators, or both.
 11. A method ofperitoneal removal of electrolytes and inflammatory mediators, themethod comprising: elevating a treatment solution container above aninfusion site of the patient; while elevating, infusing a treatmentsolution from the treatment solution into the peritoneal cavity of thepatient by way of a catheter; lowering the treatment solution containerbelow the infusion site for draining the treatment solution; whilelowering, draining, by way of the catheter, the treatment solution fromthe peritoneal cavity; and filtering electrolytes and inflammatorymediators from the treatment solution during the infusing, during thedraining, or both.
 12. The method of claim 11, wherein filteringelectrolytes and inflammatory mediators further comprises: positioning afilter in fluid communication with the catheter, the filter comprising:a proximal end; a distal end; a lumen extending between the proximal anddistal ends; and a filler within the lumen of the filter, the fillerconfigured to remove electrolytes, inflammatory mediators, or both. 13.The method of claim 12, wherein the filler is selected from the groupconsisting of: a polymer, a resin, or diffusion tubes configured toremove inflammatory mediators.
 14. The method of claim 11, whereinfiltering electrolytes and inflammatory mediators further comprises:positioning a filter in fluid communication with the catheter, thefilter comprising: a proximal end; a distal end; a lumen extendingbetween the proximal and distal ends; and a filler within the lumen ofthe filter, the filler comprising a binding agent configured toselectively bind electrolytes, inflammatory mediators, or both.
 15. Themethod of claim 14, wherein the binding agent is selected from the groupconsisting of: a polymer, a resin, or diffusion tubes configured toremove inflammatory mediators.
 16. The method of claim 11, wherein thetreatment solution comprises: saline; and a binding agent configured toselectively bind electrolytes, inflammatory mediators, or both.
 17. Themethod of claim 11, further comprising: re-instilling the treatmentsolution by, again, elevating the treatment solution container above theinfusion site.
 18. The method of claim 17, further comprising: againdraining the treatment solution by again lowering the treatment solutioncontainer to below the infusion site.
 19. A method of peritoneal removalof electrolytes and inflammatory mediators, the method comprising:implanting a filter cartridge in the peritoneal cavity of a patient;infusing a treatment solution into the peritoneal cavity of a patient;and drawing the treatment solution from the peritoneal cavity throughthe filter cartridge; wherein the filter cartridge comprises a bindingagent enclosed within a porous surgical packing material.
 20. The methodof claim 19, wherein drawing the treatment solution further comprises:pulling the treatment solution from the peritoneal cavity by way of awould drain.
 21. The method of claim 20, wherein the wound drain isfluidically coupled to a pump.
 22. The method of claim 19, furthercomprising: re-instilling the treatment solution into the peritonealcavity.
 23. The method of claim 19, wherein the binding agent isconfigured to selectively bind electrolytes, inflammatory mediators, orboth.
 24. The method of claim 23, wherein the binding agent is selectedfrom the group consisting of: a polymer, a resin, or diffusion tubesconfigured to remove inflammatory mediators.